GLP-1 drugs

Extracted Attributes

• Class of drugs

  GLP-1 receptor agonists, GLP-1 analogs, incretin mimetics

• Key drug examples

  Tirzepatide (Mounjaro, Zepbound), Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza, Saxenda), Dulaglutide (Trulicity), Exenatide (Byetta), Lixisenatide

• Market challenges

  GLP-1 pricing, counterfeit products from China, patent hacking influenced by American Invents Act

• Market leader (Q2)

  Tirzepatide (surpassed Keytruda)

• Mechanism of action

  Mimic endogenous incretin hormone GLP-1, activate GLP-1 receptor, reduce blood sugar, reduce energy intake, increase insulin secretion, suppress glucagon release, slow gastric emptying, reduce appetite

• Recommendation status

  First-line therapy for type 2 diabetes (especially with atherosclerotic cardiovascular disease or obesity) by American Diabetes Association

• Administration methods

  Subcutaneous injection, oral (Semaglutide, Eli Lilly's upcoming pill)

• Manufacturing expansion

  Eli Lilly building numerous plants in the United States

• Initial primary indication

  Type 2 diabetes

• Potential market disruption

  SSRIs market (for mental health/addictions)

• Expanded primary indications

  Weight loss, obesity

• Other indications under development

  Non-alcoholic fatty liver disease, polycystic ovary syndrome, diseases of the reward system (addictions), mental health conditions

Timeline

• The first GLP-1 receptor agonist, Exenatide, was approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes. (Source: web_search_results)

  2005

• The American Diabetes Association standards of medical care recommended GLP-1 agonists as a first-line therapy for type 2 diabetes, especially in patients with atherosclerotic cardiovascular disease or obesity. (Source: wikipedia)

  2022

• Tirzepatide became the world's top-selling drug, surpassing Keytruda. (Source: related_documents)

  Q2

GLP-1 receptor agonist

Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating. GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity and other components of the metabolic syndrome in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system such as addictions.

Web Search Results

• GLP-1 Drugs (Incretin Mimetics) - List of Brands & Generics

  GLP-1 drugs, also called GLP-1 agonists or incretin mimetics, are used to treat type 2 diabetes and support weight loss by mimicking the GLP-1 hormone. They increase insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. These effects lead to decreased caloric intake and improved satiety, and for type 2 diabetes, they improve blood sugar levels. Common examples include liraglutide and semaglutide. Clinical trials show significant weight loss and improvement in [...] Other names: GLP-1 Analogues, GLP-1 Drugs, GLP-1 Receptor Agonists, Glucagon-like Peptide 1 Agonists ## What are GLP-1 Agonists (Incretin Mimetics)? [...] - Account - Sign in - Create an account - Drugs A-Z - Pill Identifier - Drug Interaction Checker - Compare Drugs - News - Pro Edition - More Resources - Help & Support Close 1. Home 2. Drug Classes 3. Metabolic Agents 4. Antidiabetic Agents 5. GLP-1 Agonists (Incretin Mimetics) Print # GLP-1 Agonist Drugs (Incretin Mimetics) Medically reviewed by Melisa Puckey, BPharm. Last updated on April 10, 2024.

• Compare and Contrast the Glucagon-Like Peptide-1 Receptor ...

  Glucagon-like peptide-1 receptor agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) are a class of medications utilized in treating type 2 diabetes and obesity. Clinical trials show the superiority of GLP-1RA to other antihyperglycemic drugs in improving glycemic efficacy, reducing weight and blood pressure, and having a cardioprotective effect, all without the risk of hypoglycemia. These drugs have transformed the guidelines for the management of diabetes. [...] Glucagon-like peptide-1 agonists (GLP-1RA) are analogs of GLP-1, a gut-derived peptide hormone that exhibits a glucose-lowering effect via stimulation of insulin secretion from pancreatic islets in response to an oral glucose load, known as the incretin effect. Unlike the natural peptide hormone, synthetic GLP-1 is resistant to degradation by the dipeptidyl peptidase 4 (DPP-4) enzyme, and thus it has a longer half-life. The GLP-1 activity in patients with type 2 diabetes may be decreased.GLP-1 [...] FDA-approved GLP-1 receptor agonists for glycemic control include: Dulaglutide (subcutaneous-SC) Exenatide injectable solution subcutaneous Exenatide injectable suspension SC Liraglutide SC Liraglutide/insulin degludec Lixisenatide/insulin glargine Semaglutide (oral, SC) Tirzepatide (dual GIP/GLP-1 receptor agonist) FDA-approved GLP-1 agonists for weight loss include: Semaglutide SC Liraglutide SC(

• GLP-1 diabetes and weight-loss drug side effects - Harvard Health

  GLP-1 drugs, also called GLP-1 agonists, are shortened names for glucagon-like peptide-1 receptor agonists. GLP-1 receptor agonists mimic the GLP-1 hormone that is naturally released in the gastrointestinal tract in response to eating. [...] | GLP-1 drugs | | Generic name | Brand name | Approved use | | Semaglutide injection | Ozempic | Type 2 diabetes | | Semaglutide injection | Wegovy | Weight loss | | Semaglutide tablets | Rybelsus | Type 2 diabetes | | Liraglutide | Victoza | Type 2 diabetes | | Liraglutide | Saxenda | Weight loss | | Tirzepatide | Mounjaro | Type 2 diabetes | | Tirzepatide | Zepbound | Weight loss | | Dulaglutide | Trulicity | Type 2 diabetes | | Exenatide | Byetta | Type 2 diabetes | [...] Ten GLP-1 drugs are FDA-approved to treat either type 2 diabetes or weight loss. Some GLP-1 agonists have the same generic name but are marketed under a different brand name and are approved for a different purpose, depending on the dose and how they are taken. | |

• Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI

  Structurally, these agents fall into 2 broad categories: human GLP-1 backbone agents and exendin-4 backbone agents. Below are FDA-approved GLP-1 agonists. Human GLP-1 backbone: Dulaglutide Albiglutide - discontinued Liraglutide Semaglutide Exendin-4 backbone: Exenatide (2 formulations) Lixisenatide - discontinued Tirzepatide is a GIP analog that activates both the GLP-1 and GIP receptors. [...] Many formulations of GLP-1 agonists were historically injectable. GLP-1 agonists are generally administered subcutaneously due to poor oral bioavailability. Liraglutide is dosed daily. Dulaglutide and semaglutide dosing is weekly, and exenatide can be dosed twice daily or once weekly. Recently, the FDA approved an oral formulation of Semaglutide. Researchers have suspended trials investigating taspoglutide as a novel GLP-1 analog due to GI side effects and hypersensitivity reactions.( [...] Summary of dosing frequency for some commonly prescribed GLP-1 receptor agonists: Dulaglutide - weekly Liraglutide - daily Semaglutide - weekly subcutaneously, daily orally Exenatide BID - twice daily Exenatide QW - weekly Tirzepatide - weekly Albiglutide - weekly (withdrawn from the market)(

• GLP-1 receptor agonists beyond diabetes management - The Lancet

  Since 2005, the landscape of available GLP-1 RAs has greatly expanded alongside the number of their therapeutic indications. Beyond exenatide, the class now includes liraglutide, dulaglutide, lixisenatide, tirzepatide, and semaglutide (marketed as Ozempic or Wegovy). Both liraglutide and dulaglutide have shown cardiovascular risk reduction in landmark trials (LEADER and REWIND, respectively), underscoring their dual benefits for glucose homeostasis and cardiovascular health. Semaglutide is [...] The first glucagon-like peptide-1 receptor agonist (GLP-1 RA], exenatide, was approved by US Food and Drug Administration in 2005, and was initially indicated for the treatment of type 2 diabetes. Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of a lizard native to North America that can survive extended periods without food. Exendin-4 can mimic the action of GLP-1, an incretin regulating glucose homeostasis. GLP-1 acts on pancreatic β cells to enhance insulin